| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 10,525 | 13,124 | ||
| General and administrative | 4,426 | 5,558 | ||
| Total operating expenses | 14,951 | 18,682 | ||
| Loss from operations | -14,951 | -18,682 | ||
| Interest income | 1,532 | 1,683 | ||
| Interest expense | 650 | 646 | ||
| Loss on debt extinguishment | 0 | 0 | ||
| Other, net | 112 | 61 | ||
| Total other income, net | 770 | 976 | ||
| Net loss | -14,181 | -17,706 | ||
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.52 | -0.65 | ||
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.52 | -0.65 | ||
| Weighted-average number of common shares outstanding, basic (in shares) | 27,104,000 | 27,072,000 | ||
| Weighted-average number of common shares outstanding, diluted (in shares) | 27,104,000 | 27,072,000 | ||
Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience, Inc. (ANRO)